<DOC>
	<DOCNO>NCT02851602</DOCNO>
	<brief_summary>HDL obese non-diabetic patient show major alteration function thus cardio-protective effect . These alteration could explain quantitative qualitative anomaly phospholipid sphingolipids HDL . These molecule play major role HDL function probably present early modification obesity , even onset glycaemia deregulation . The aim study show presence qualitative quantitative modification phospholipid sphingolipids HDL obese patient compare HDL non-obese control .</brief_summary>
	<brief_title>Phospholipid Sphingolipid Composition High-density Lipoproteins ( HDL ) Obese Non-diabetic Patients With Metabolic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<criteria>age &gt; 18 year fast glycaemia &lt; 1.10 g/l waist circumference &gt; 102 cm men 88 cm woman ( criterion NCEP/ATP III ) 2 criterion among follow 3 ( NCEP/ATP III criterion metabolic syndrome ) : triglyceridaemia ≥ 1.50 g/l HDL cholesterol &lt; 0.40 g/l men 0.50 g/l woman arterial blood pressure ≥ 130/85 mmHg treatment arterial hypertension patient provide write consent INCLUSION CRITERIA FOR HEALTHY SUBJECTS age &gt; 18 year fast glycaemia &lt; 1.10 g/l waist circumference &lt; 102 cm men 88 cm woman triglyceridaemia &lt; 1.50 g/l HDL cholesterol ≥ 0.40 g/l men 0.50 g/l woman Healthy subject provide write consent Persons without national health insurance cover Diabetes Diseases interfere lipoprotein metabolism ( dysthyroidism control treatment , kidney liver disease ) Treatments interfere lipoprotein metabolism ( lipidlowering agent , oestrogen , corticoid , retinoids , antiretroviral agent ) Pregnancy/breast feed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>